


AMENDMENTS TO THE CLAIMS

1. (Currently Amended): A compound of the formula:



and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein


represents a single or double bond;

B is $-W_i-CO-X_j-Y$ wherein Y is COR^2 or an isostere thereof and R^2 is hydrogen, or is straight or branched chain alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each optionally substituted with halo, alkyl, SR, OR, NR₂, OCOR, NRCOR, NRCONR₂, NRSO₂R, NRSO₂NR₂, OCONR₂, CN, COOR, CONR₂, COR, or R₃Si wherein each R is independently H, alkyl, alkenyl or aryl ~~or a noninterfering substituent~~, each of W and X is a substituted or unsubstituted alkylene, alkenylene or alkynylene a spacer of 2-6 Å, and each of i and j is independently 0 or 1;

each R^3 is independently halo, alkyl, OCOR, OR, NRCOR, SR, or NR₂, wherein R is H, alkyl or aryl ~~a noninterfering substituent~~, where n is 0-3;

Z^3 is NR^7 or O; wherein R^7 is H or R^7 is H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, SOR, SO₂R, RCO, COOR, alkyl-COR, SO₃R, CONR₂, SO₂NR₂, CN, CF₃, NR₂, OR, alkyl-SR, alkyl-SOR, alkyl-SO₂R, alkyl-OCOR, alkyl-COOR, alkyl-CN, alkyl-CONR₂, or R₃Si, wherein each R is independently H, alkyl, alkenyl or aryl ~~a noninterfering substituent~~;

one Z^2 is CA or CR^8A and the other is CR^1 , CR^1_2 , NR^6 or N wherein each R^1 , R^6 and R^8 is independently hydrogen or a C₁₋₄ alkyl ~~noninterfering substituent~~; wherein A is:



Ar is an aryl optionally substituted with 0-5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR₂, SR, SOR, SO₂R, OCOR, NRCOR, NRCONR₂, NRCOOR, OCONR₂, RCO, COOR, alkyl-OOR, SO₃R, CONR₂, SO₂NR₂, NRSO₂NR₂, CN, CF₃, R₃Si, and NO₂, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof, and wherein two of said optional substituents on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members ~~an aryl group substituted with 0-5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring;~~

each R⁴ is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR₂, SR, SOR, SO₂R, OCOR, NRCOR, NRCONR₂, NRCOOR, OCONR₂, RCO, COOR, alkyl-OOR, SO₃R, CONR₂, SO₂NR₂, NRSO₂NR₂, CN, CF₃, R₃Si, and NO₂, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and two of R⁴ on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members, or R⁴ is =O or an oxime, oxime ether, oxime ester or ketal thereof, a noninterfering substituent where m is 0-4;

each of L¹ and L² is a linker; and

L¹ is CO, SO₂, H or CH₂; and

L² is alkylene (1-4C) or alkenylene (1-4C) optionally substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR₂, SR, SOR, SO₂R, OCOR, NRCOR, NRCONR₂, NRCOOR, OCONR₂, RCO, COOR, alkyl-OOR, SO₃R, CONR₂, SO₂NR₂, NRSO₂NR₂, CN, CF₃, R₃Si, and NO₂, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof, and wherein two substituents on L² can be joined to form a non-aromatic saturated or unsaturated ring that includes 0-3 heteroatoms which are O, S and/or N and which contains 3 to 8 members or said two substituents can be joined to form a carbonyl moiety or an oxime, oxime ether, oxime ester or ketal of said carbonyl moiety.

~~the distance between the atom of Ar linked to L² and the center of the β ring is no more than 24Å.~~

2. (Previously Presented): The compound of claim 1 wherein B is $-\text{COX}_j\text{COR}^2$, and wherein R² is H, or is straight or branched chain alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, or heteroarylalkyl, each optionally substituted with halo, alkyl, heteroalkyl, SR, OR, NR₂, OCOR, NRCOR, NRCONR₂, NRSO₂R, NRSO₂NR₂, OCONR₂, CN, COOR, CONR₂, COR, or R₃Si wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof, or

wherein R² is OR, NR₂, SR, NRCONR₂, OCONR₂, or NRSO₂NR₂, wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof, and wherein two R attached to the same atom may form a 3-8 member ring and wherein said ring may further be substituted by alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, each optionally substituted with halo, SR, OR, NR₂, OCOR, NRCOR, NRCONR₂, NRSO₂R, NRSO₂NR₂, OCONR₂, or R₃Si wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof wherein two R attached to the same atom may form a 3-8 member ring, optionally substituted as above defined; and

X, if present, is alkylene.

3. (Previously Presented): The compound of claim 1 wherein Y is an isostere of COR².

4. (Previously Presented): The compound of claim 3 wherein Y is tetrazole; 1,2,3-triazole; 1,2,4-triazole; or imidazole.

5. (Previously Presented): The compound of claim 1 wherein each of i and j is 0.

6. (Previously Presented): The compound of claim 2 wherein j is 0.

7. (Previously Presented): The compound of claim 1 wherein Z³ is NR⁷.

8. (Previously Presented): The compound of claim 7 wherein R^7 is H or is optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, or is SOR, SO_2R , RCO, COOR, alkyl-COR, SO_3R , $CONR_2$, SO_2NR_2 , CN, CF_3 , NR_2 , OR, alkyl-SR, alkyl-SOR, alkyl- SO_2R , alkyl-OCOR, alkyl-COOR, alkyl-CN, alkyl- $CONR_2$, or R_3Si , wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof.

9. (Previously Presented): The compound of claim 8 wherein R^7 is H, or is optionally substituted alkyl, or acyl.

10. (canceled)

11. (canceled)

12. (Currently Amended): The compound of claim ~~1~~ 14 wherein L^1 is CO.

13-14. (canceled)

15. (canceled)

16. (Previously Presented): The compound of claim ~~15~~ 1 wherein L^2 is unsubstituted alkylene.

17. (Previously Presented): The compound of claim ~~15~~ 1 wherein L^2 is unsubstituted methylene, methylene substituted with alkyl, or $-CH=$.

18. (canceled)

19. (Previously Presented): The compound of claim ~~18~~ 1 wherein Ar is optionally substituted phenyl.


20. (Previously Presented): The compound of claim 19 wherein said optional substitution is by halo, OR, or alkyl.
21. (Previously Presented): The compound of claim 20 wherein said phenyl is unsubstituted or has a single substituent.
22. (canceled)
23. (Currently Amended): The compound of claim 1 ~~22~~ wherein each R^4 is halo, OR, or alkyl.
24. (Previously Presented): The compound of claim 23 wherein m is 0, 1, or 2.
25. (Previously Presented): The compound of claim 24 wherein m is 2 and both R^4 are alkyl.
26. (Previously Presented): The compound of claim 1 wherein each R^3 is halo, alkyl, heteroalkyl, OCOR, OR, NRCOR, SR, or NR_2 , wherein R is H, alkyl, aryl, or heteroforms thereof.
27. (Previously Presented): The compound of claim 26 wherein R^3 is halo or alkoxy.
28. (Previously Presented): The compound of claim 27 wherein n is 0, 1 or 2.
29. (Previously Presented): The compound of claim 1 wherein L^1 is coupled to the β ring at the 5- position.
30. (Previously Presented): The compound of claim 1 wherein Z^2 at position 3 is CA or CH^1A .
31. (Previously Presented): The compound of claim 30 wherein the Z^2 at position 2 is CR^1 or CR^1_2 .

32. (Previously Presented): The compound of claim 31 wherein R^1 is hydrogen, or is alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR_2 , SR, SOR, SO_2R , OCOR, NRCOR, $NRCONR_2$, $NRCOOR$, $OCOR_2$, RCO, COOR, alkyl-OOR, SO_3R , $CONR_2$, SO_2NR_2 , $NRSO_2NR_2$, CN, CF_3 , R_3Si , and NO_2 , wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and two of R^1 can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members.

33. (Previously Presented): The compound of claim 32 wherein each R^1 is selected from the group consisting of H, alkyl, acyl, aryl, arylalkyl, heteroalkyl, heteroaryl, halo, OR, NR_2 , SR, NRCOR, alkyl-OOR, RCO, COOR, and CN, wherein each R is independently H, alkyl, or aryl or heteroforms thereof.


34. (Previously Presented): The compound of claim 30 wherein Z^2 at position 2 is N or NR^6 .


35. (Previously Presented): The compound of claim 34 wherein R^6 is H, or alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, or is SOR, SO_2R , RCO, COOR, alkyl-COR, SO_3R , $CONR_2$, SO_2NR_2 , CN, CF_3 , or R_3Si wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof.


36. (Previously Presented): The compound of claim 1 wherein  represents a double bond.


37. (canceled)


38. (Previously Presented): The compound of claim 1 wherein the compound of formula (1) is selected from the group consisting of:

















































39. (Previously Presented): A pharmaceutical composition which composition comprises

a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with at least one pharmaceutically acceptable carrier.

40-41. (canceled)

42-44. (canceled)